Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Gazi Abdulhay

Gynecologic Oncology Upland, PA Medical Doctor

NPI 1548210024 CMS profile 205535

1 Medical Center Blvd, Cancer Center, Suite 441, Upland, PA 19013

Open in the dashboard

General payments

$10,361

63 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Gazi Abdulhay of Upland, PA is reported in the CMS Open Payments database as having received $10,361 across 63 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 80th percentile of Gynecologic Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $85 3
2022 General $8,070 9
2021 General $54 2
2020 General $75 4
2019 General $2,077 45

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gazi Abdulhay
  • Gynecologic Oncology median
  • Middle half of Gynecologic Oncology
  • National median

In program year 2025, general payments to Gazi Abdulhay were reported at $0. Among 1,179 Gynecologic Oncology profiles paid that year, the median was $305 and the middle half received between $111 and $1,499.

Show as a table
Year Gazi Abdulhay Gynecologic Oncology median Middle half National median
2019 $2,077 $287 $113–$1,548 $163
2020 $75 $223 $59–$2,164 $114
2021 $54 $193 $68–$1,139 $132
2022 $8,070 $252 $90–$1,151 $149
2023 $85 $281 $102–$1,419 $160
2024 $0 $308 $108–$1,502 $164
2025 $0 $305 $111–$1,499 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Intuitive Surgical, Inc. $8,079 9 payments
  2. Olympus Corporation of the Americas $1,203 11 payments
  3. TESARO, Inc. $243 7 payments
  4. Becton, Dickinson and Company $177 1 payment
  5. Kyowa Kirin, Inc. $79 4 payments
  6. AstraZeneca Pharmaceuticals LP $74 4 payments
  7. GlaxoSmithKline, LLC. $62 3 payments
  8. Karyopharm Therapeutics Inc. $54 2 payments
  9. CooperSurgical, Inc. $48 1 payment
  10. Genentech USA, Inc. $47 3 payments
  11. Other $296 18 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Education $7,557 4 payments
  2. Food and Beverage $1,541 51 payments
  3. Travel and Lodging $1,215 7 payments
  4. Royalty or License $48 1 payment
Products named General payments · program years 2019–2023
  1. DAVINCI XI $7,500 3 payments
  2. ThunderBeat $1,203 11 payments
  3. Da Vinci Surgical System $579 6 payments
  4. ZEJULA $306 10 payments
  5. PROGEL $177 1 payment
  6. SANCUSO $79 4 payments
  7. LYNPARZA $61 3 payments
  8. XPOVIO $54 2 payments
  9. Advincula Delineator Uterine Manipulator $48 1 payment
  10. Avastin $47 3 payments
  11. Other $432 27 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

63 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gynecologic Oncology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record